Yuhan Corp. announced Wednesday it has licensed GI Innovation?s next-generation allergy treatment pipeline in a deal that could potentially total $1.2 billion. ?I am very pleased by this collaboration with GI Innovation to develop the next-generation allergy treatment across all four major allergic diseases; allergic asthma, chronic urticaria, atopic dermatitis and food allergy, improving the lives of pediatric and adult patients who suffer from allergies? said Yuhan President and CEO Lee Jung-hee. Under the deal, Yuhan has global rights, excluding Japan, to develop and commercialize GI-301, while. GI Innovation will collaborate on the development. Yuhan will pay an upfront, nonrefundable $17 million to GI Innovation, and pay additional royalties upon milestone achievements. The deal could reach $1.2 billion in case of the completion of development and successful commercialization.